We found the winning formula and how to achieve high efficacy
In the closing days of 2020, as a new coronavirus variant cast fresh uncertainty over Britain's fragile recovery, AstraZeneca announced it had resolved the dosing ambiguity that had shadowed its Oxford-developed vaccine — claiming a formula capable of matching rival efficacy while offering the practical advantages of lower cost and ordinary refrigeration. The announcement arrived on the eve of regulatory review, carrying both the promise of an accelerated national vaccination campaign and the quiet acknowledgment that the virus, still evolving, might yet demand new answers.
- A dosing error during earlier trials had split the data and shaken confidence in the Oxford vaccine, leaving its credibility in question just as Britain needed it most.
- A new, faster-spreading variant was already overwhelming parts of the country, turning the race to approve and distribute vaccines into something closer to a crisis response.
- AstraZeneca's CEO declared the problem solved — a refined two-dose regimen, he claimed, would deliver high efficacy and complete protection against severe disease.
- The vaccine's cold-chain simplicity and lower price point made it uniquely suited to rapid, wide-scale deployment in ways that Pfizer's ultra-frozen doses could not match.
- Even as approval neared, the company was quietly developing variant-specific versions, a contingency that underscored how much remained unknown about the road ahead.
In late December 2020, Britain's vaccination effort stood at a turning point. Cases were rising, a new variant was spreading rapidly, and the Oxford-developed AstraZeneca vaccine — the country's most anticipated second weapon — had been clouded by confusing trial results. Interim data from studies in Britain and Brazil had shown an average efficacy of 70 percent, well below the figures reported by Pfizer and Moderna. Stranger still, the data revealed that volunteers who received a mistaken half-dose followed by a full dose fared better — 90 percent efficacy — than those who received two full doses, at only 62 percent. The accidental discrepancy had invited serious scrutiny.
Now, AstraZeneca's chief executive Pascal Soriot told the Sunday Times that researchers had found the winning formula. With the correct two-dose regimen, he said, the vaccine would achieve efficacy comparable to its rivals — and crucially, would offer complete protection against severe COVID-19. British regulators were expected to rule on approval within days.
What set the Oxford vaccine apart was not efficacy alone but practicality. Unlike Pfizer's doses, which required storage at minus 70 degrees Celsius and strained distribution infrastructure, AstraZeneca's vaccine needed only standard refrigeration and cost considerably less. For a country trying to vaccinate millions at speed, those differences were decisive.
Britain had already begun its Pfizer rollout earlier that month, the first Western nation to do so. AstraZeneca's approval would allow that pace to accelerate significantly. But uncertainty lingered at the edges of the optimism. Soriot acknowledged that no one yet knew whether the vaccine would hold against the emerging mutation, and the company was already preparing variant-specific versions as a precaution — a quiet admission that the virus had not finished presenting new challenges.
Britain's vaccination campaign was about to gain a second major weapon. In late December 2020, as cases climbed and a new coronavirus variant spread across the country, AstraZeneca announced it had cracked the problem that had dogged its Oxford-developed vaccine for weeks. The company's chief executive, Pascal Soriot, told the Sunday Times that researchers had found what he called the winning formula—a dosing strategy that would deliver efficacy matching the leading competitors, with the added advantage of being far cheaper and easier to distribute.
The announcement came as regulatory approval loomed. Just weeks earlier, in November, AstraZeneca had released interim trial results from large-scale studies in Britain and Brazil that showed an average efficacy of 70 percent—a figure that landed awkwardly between Pfizer and Moderna's reported rates above 90 percent. The company's own data revealed why: volunteers who received a half dose followed by a full dose a month later showed 90 percent efficacy, while those given two full doses showed only 62 percent protection. A dosing error during the trial had created this split, and critics questioned whether the results could be trusted.
Now, Soriot claimed the company had solved it. With the right two-dose regimen, he said, the vaccine would achieve high efficacy comparable to rivals. More striking still, he asserted the vaccine offered 100 percent protection against severe COVID-19—the outcome that mattered most in a pandemic. The British regulator was expected to rule on approval within days.
What made the Oxford vaccine genuinely valuable was not just efficacy but logistics. Pfizer's shot required storage at minus 70 degrees Celsius, a temperature that strained supply chains and limited where doses could be kept. AstraZeneca's vaccine needed only standard refrigeration. It was also substantially cheaper. For a country racing to vaccinate millions and facing a new variant that threatened to overwhelm hospitals, these practical advantages mattered as much as the efficacy numbers.
Britain had already begun rolling out Pfizer doses in early December, becoming the first Western nation to do so. Now, with AstraZeneca's vaccine potentially approved, the vaccination pace could accelerate. The new variant circulating across British territory made speed urgent.
Yet uncertainty remained. Soriot acknowledged that no one could be certain the vaccine would remain effective against the emerging mutation. The company was preparing variant-specific versions as insurance, he said—a precaution born from the knowledge that the virus was still evolving. For now, he believed the current vaccine should still work. But belief was not certainty, and the company was already planning for the possibility that it might not.
Citações Notáveis
We believe we have found the winning formula and how to achieve efficacy that, with two doses, is as high as the others— Pascal Soriot, AstraZeneca CEO
The vaccine should remain effective against the new variant, but we cannot be certain, so we will conduct some tests— Pascal Soriot, AstraZeneca CEO
A Conversa do Hearth Outra perspectiva sobre a história
Why did the half-dose, full-dose approach work better than two full doses? That seems backward.
It does seem counterintuitive. The theory is that the first smaller dose primes the immune system differently—gives it a gentler introduction to the viral vector—so when the full dose arrives, the response is stronger and more durable. Two full doses at once may have overwhelmed the system or triggered a different immune pathway. But honestly, they stumbled onto it partly by accident during the trial.
And the company is claiming 100 percent protection against severe disease. How confident should we be in that number?
It's a narrower claim than it sounds. They're not saying no one gets infected. They're saying no one in their trials got severely ill or died. That's meaningful for a healthcare system, but it's also a smaller dataset than the overall efficacy numbers. Time will tell if it holds up in the real world.
The storage temperature advantage—how much does that actually change things on the ground?
Enormously. Minus 70 degrees means specialized freezers, trained handlers, limited locations. Standard refrigeration means any clinic, any pharmacy, any mobile unit can store it. For a country trying to vaccinate millions fast, that's the difference between a bottleneck and a highway.
What about the new variant? Is the company just guessing that it will still work?
Essentially, yes. They haven't tested it yet. They're preparing backup versions just in case, but they're hoping they won't need them. It's a reasonable precaution, but it also shows how much uncertainty still exists about what's coming next.